HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women

被引:14
|
作者
Vogelvang, TE
Mijatovic, V
Kenemans, P
Teerlink, T
van der Mooren, MJ
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, Project Aging Women, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, ICaR, NL-1007 MB Amsterdam, Netherlands
关键词
HMR; 3339; raloxifene; menopause; lipids; lipoprotein(a); homocysteine; endothelin-1;
D O I
10.1016/j.fertnstert.2004.05.093
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the short-term effects of HMR 3339 in comparison with raloxifene and placebo on cardiovascular risk factors. Design: A multicenter, randomized, placebo-controlled, double-blind, dose-ranging study. Setting: Gynecologic outpatient department. Patient(s): One hundred eighteen healthy nonhysterectomized postmenopausal women. Intervention(s): Participants received daily placebo (n = 22), 2.5 mg of HMR 3339 (n = 25), 10 mg of HMR 3339 (n = 24), 50 mg of HMR 3339 (n = 24), or 60 mg of raloxifene (n = 23) for 12 weeks followed by a 2-week washout period. Main Outcome Measure(s): Blood concentrations of lipids measured at baseline, and after 2, 4, 8, 12, and 14 weeks, and of lipoprotein(a), homocysteine, and endothelin-1 measured at baseline, and after 4 and 12 weeks. Result(s): After 12 weeks of treatment with HMR 3339, compared with placebo, serum total cholesterol was reduced (10 mg of HMR 3339: -9.7%; 50 mg of HMR 3339: -15.2%), low-density lipoprotein (LDL)-cholesterol (10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -24.2%) and plasma homocysteine concentrations (2.5 mg of HMR 3339: -3.9%; 10 mg of HMR 3339: -10.8%; 50 mg of HMR 3339: -13.8%), suggesting a dose-dependent effect of HMR 3339. These effects were already apparent after 2 weeks of treatment for total cholesterol and LDL-cholesterol, and after 4 weeks of treatment for homocysteine. After 12 weeks, raloxifene, compared with placebo, significantly decreased total cholesterol (-10.5%), LDL-cholesterol (-15.0%), and triglycerides (-16.9%), but not homocysteine. High-density lipoprotein-cholesterol, lipoprotein(a), and endothelin-1 showed no significant changes in any of the active treatment groups. Conclusion(s): HMR 3339 reduces total cholesterol, LDL-cholesterol, and homocysteine concentrations in postmenopausal women. (C) 2004 by American Society for Reproductive Medicine.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
  • [41] DIETARY-CHOLESTEROL RESULTS IN MODEST INCREASES IN BOTH LOW-DENSITY AND HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL IN HEALTHY-YOUNG WOMEN
    KARMALLY, W
    SIDDIQUI, M
    NGAI, C
    HOLLERAN, S
    RAMAKRISHNAN, R
    GINSBERG, HN
    CIRCULATION, 1994, 90 (04) : 235 - 235
  • [42] Feeding tomatoes to hamsters reduces their plasma low-density lipoprotein cholesterol and triglycerides
    Friedman, M
    Fitch, TE
    Yokoyama, WH
    JOURNAL OF FOOD SCIENCE, 2000, 65 (05) : 897 - 900
  • [43] Plant stanol esters in low-fat yogurt reduces total and low-density lipoprotein cholesterol and low-density lipoprotein oxidation in normocholesterolemic and mildly hypercholesterolemic subjects
    Hyun, YJ
    Kim, OY
    Kang, JB
    Lee, JH
    Jang, Y
    Liponkoski, L
    Salo, P
    NUTRITION RESEARCH, 2005, 25 (08) : 743 - 753
  • [44] Ezetimibe significantly reduces low-density lipoprotein cholesterol in homozygous familial hypercholesterolemia
    Gagne, C
    Gaudet, D
    Bruckert, E
    Ponsonnet, D
    Lipka, L
    LeBeaut, A
    Suresh, R
    Abreu, P
    Veltri, E
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 227A - 227A
  • [45] Apolipoprotein B, Low-Density Lipoprotein Particle Number, Non-High-Denisity Lipoprotein Cholesterol, Low-Density Lipoprotein Cholesterol, and Total Cholesterol for Atherosclerotic Cardiovascular Disease Risk Prediction in Young Adults
    Wilkins, John T.
    Ning, Hongyan
    Sawicki, Konrad
    Sawicki, Konrad T.
    Sniderman, Allan D.
    Otvos, James D.
    Rana, Jamal S.
    Murthy, Venkatesh
    Murthy, Venkatesh L.
    Shah, Ravi V.
    Allen, Norrina B.
    Lloyd-Jones, Donald
    CIRCULATION, 2023, 147
  • [46] Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism: Of Mice and Man
    Stein, Evan A.
    Raal, Frederick J.
    CIRCULATION, 2013, 127 (24) : 2372 - 2374
  • [47] A Worthy Finding: Decrease in Total Cholesterol and Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism
    Zhao, Meng
    Liu, Lu
    Wang, Fei
    Yuan, Zhongshang
    Zhang, Xu
    Xu, Chao
    Song, Yongfeng
    Guan, Qingbo
    Gao, Ling
    Shan, Zhongyan
    Zhang, Haiqing
    Zhao, Jiajun
    THYROID, 2016, 26 (08) : 1019 - 1029
  • [48] ASSOCIATION OF COFFEE INTAKE WITH APOLIPOPROTEIN-B, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, AND TOTAL CHOLESTEROL IN MEN
    WILLIAMS, P
    WOOD, P
    VRANIZAN, K
    ALBERS, J
    GARAY, S
    TAYLOR, C
    ARTERIOSCLEROSIS, 1984, 4 (05): : A549 - A549
  • [49] Effect of liposome-encapsulated hemoglobin on triglyceride, total cholesterol, low-density lipoprotein, and high-density lipoprotein cholesterol measurements
    Abdullah, F
    Whiteford, M
    Mathiak, G
    Ovadia, P
    Rudolph, A
    Neville, LF
    Rabinovici, R
    LIPIDS, 1997, 32 (04) : 377 - 381
  • [50] APPLICATION OF A NOVEL METHOD FOR ESTIMATING LOW-DENSITY LIPOPROTEIN CHOLESTEROL AT LOW LEVELS
    Martin, Seth Shay
    Meeusen, Jeffrey W.
    Donato, Leslie
    Jaffe, Allan
    Sokoll, Lori J.
    Jones, Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1926 - 1926